Drug Profile
Research programme: malaria therapeutics - Genaera
Alternative Names: MSI 1459Latest Information Update: 08 Aug 2007
Price :
$50
*
At a glance
- Originator Genaera Corporation
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Malaria
Most Recent Events
- 28 Mar 2001 Magainin Pharmaceuticals is now called Genaera Corporation
- 06 Jul 1998 Preclinical development for Malaria in USA (Unknown route)